Brief: Autolus Therapeutics Presents Positive Results From Blood Cancer Drug Trial At ASCO
02/06/2023 12:05
June 2 (Reuters) - Autolus Therapeutics PLC AUTL.O :
* AUTOLUS THERAPEUTICS PRESENTS POSITIVE RESULTS FROM
PIVOTAL
PHASE 2 FELIX STUDY IN ADULT R/R B-ALL AT ASCO
* AUTOLUS THERAPEUTICS PLC - 76% OF PATIENTS TREATED WITH
OBE-CEL
IN FELIX STUDY ACHIEVED A RESPONSE (CR/CRI), PRIMARY ENDPOINT
HAS BEEN MET
Source text for Eikon: ID:nGNX8jlD3j
Further company coverage: AUTL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Autolus Therapeutics
See all newsBrief: Autolus Therapeutics PLC Unit Enters Master Service Agreement With AGC Biologics
Brief: Autolus Therapeutics Appoints Ryan Richardson To Board Of Directors
Brief: Nice Recommends Aucatzyl As A Treatment Option For Adult Patients With Lymphoblastic Leukemia
Brief: Autolus Therapeutics’ Car T Therapy Aucatzyl® (Obecabtagene Autoleucel) Granted European Marketing Authorization For Adult Patients
Brief: Autolus Therapeutics Announces Inducement Grants